Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Novartis AG ADS (NY: NVS)
73.81 USD  -0.81 (-1.09%)
Streaming Delayed Price  /  Updated: 3:59 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Novartis AG ADS
 
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
May 02, 2007
- Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 percent in hip fractures Read More
from PR Newswire
Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
April 30, 2007
from PR Newswire
Novartis Marks First Community Partnership Day in the Bay Area and Opens Community Park in Emeryville
April 26, 2007
from PR Newswire
Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment of Nicotine Addiction
April 25, 2007
Cytos Biotechnology may Receive up to CHF 600 Million in Upfront and Potential Milestone Payments Plus Royalties on net Sales Read More
from PR Newswire
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
April 17, 2007
-- Reclast is the first new treatment in nearly a decade for Paget's disease of the bone, which affects about one million people in the US Read More
from PR Newswire
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
April 12, 2007
- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST) Read More
from PR Newswire
Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for USD 5.5 Billion to Nestlé
April 12, 2007
Divestiture Program Completed With Novartis Business Portfolio Now Entirely Focused on Healthcare Read More
from Marketwired News Releases
Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for US$5.5 Billion to Nestle
April 12, 2007
from GlobeNewswire News Releases
Novartis Suspends US Marketing and Sales of Zelnorm(R) in Response to Request from FDA
March 30, 2007
* Retrospective analysis of pooled clinical trial data shows numerical imbalance in cardiovascular events in patients taking Zelnorm compared to those on placebo Read More
from PR Newswire
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
March 26, 2007
* New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone Read More
from PR Newswire
XOMA Reports 2006 Results
March 08, 2007
Significant Revenue Growth and Pipeline Advancement Characterize 2006 Read More
from GlobeNewswire News Releases
Seven Summits Research Releases Comments on GOOG, CVX, KO, NVDA, and NVS
March 06, 2007
from PR Newswire
Tekturna(R) -- the First New Type of High Blood Pressure Medicine in More Than a Decade -- Receives Its First Approval in the US
March 06, 2007
from Marketwired News Releases
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
March 06, 2007
- Tekturna, the first approved direct renin inhibitor, acts on one of the body's key regulators of blood pressure by targeting renin Read More
from PR Newswire
A.M. Best Affirms Ratings of Gerber Life Insurance Company
March 05, 2007
from Business Wire News Releases
Zacks Analyst Blog Highlights: Xoma, Novartis, Salix Pharmaceuticals and Shire Pharmaceuticals
March 05, 2007
from Business Wire News Releases
Joe Montana Visits Miami to Raise Awareness of High Blood Pressure (Hypertension) and Its Impact on Health
February 04, 2007
Joe Montana Is Joined by Dr. James Rippe to Tackle High Blood Pressure, a Major Health Issue; Hypertension Affects Approximately 72 Million Adults in the U.S., According to the American Heart... Read More
from Marketwired News Releases
IR Global Rankings Announces Dates for Its 2007 IR Workshops and Award Ceremonies
January 30, 2007
from PR Newswire
Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan
January 22, 2007
from JCN Newswire
Novartis Strategic Healthcare Portfolio Drives Sustained Strong Performance With Record Full-Year Results in 2006
January 18, 2007
from Marketwired News Releases
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
December 29, 2006
from Business Wire News Releases
/C O R R E C T I O N -- Novartis Pharmaceuticals Corporation/
December 22, 2006
from PR Newswire
/ CORRECTION - Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients With High Blood Pressure
December 22, 2006
from Marketwired News Releases
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients With High Blood Pressure
December 22, 2006
from Marketwired News Releases
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
December 22, 2006
- Exforge offers in one tablet the complementary actions of valsartan and amlodipine besylate, two of the most prescribed branded antihypertensive medicines Read More
from PR Newswire
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
December 22, 2006
- Exforge offers in one tablet the complementary actions of valsartan and amlodipine besylate, two of the most prescribed branded antihypertensive medicines Read More
from PR Newswire
Savient Pharmaceuticals Announces Appellate Court Decision in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
December 12, 2006
from Business Wire News Releases
IR Global Rankings Invite Investors and Analysts to Choose the Best IR Website by Direct Vote
December 12, 2006
from PR Newswire
Savient Pharmaceuticals Announces Modification of Temporary Restraining Order in Patent Infringement Lawsuit against Sandoz Pharmaceuticals and Upsher-Smith Laboratories
December 11, 2006
from Business Wire News Releases
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
December 11, 2006
- New data support US and EU submissions of next-generation targeted therapy offering hope to patients with resistance or intolerance to Gleevec Read More
from PR Newswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here